Enhanced passive safety surveillance of the quadrivalent inactivated split-virion influenza vaccine (IIV4) in Finland during the 2019/20 influenza season
Bibliographic Data
| ID | 15375006 |
|---|---|
| Authors | Anne-Laure Chabanon (0000-0002-5866-5801, Sanofi (France), corresponding author), Sophie Wagué (Sanofi (France)), Annick Moureau (0000-0002-5306-2833, Sanofi (France)), M Nissilä (0000-0002-3327-0141, Turku Centre for Biotechnology), Laurence Serradell (0000-0003-3683-8086, Sanofi (France)) |
| Year | 2021 |
| Volume | 21 |
| Issue | 1 |
| Pages | 358-358 |
| Publication date | 2021-02-15 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | BMC Public Health (JOURNAL) |
| Journal identifiers | ISSN: 1471-2458 • E-ISSN: 1471-2458 |
| Publisher | BioMed Central (PUBLISHER • GB) |
| DOI | 10.1186/s12889-021-10378-8 |
| PMID | 33588815 |
| OpenAlex | W3129914096 |
| Language | EN |
| Citations received | 1 |
| References cited | 6 |
No clinically significant changes in what is known or expected for IIV4 was reported for the 2019/20 season, which supports the overall safety profile
Adverse effect · Antibody · Biostatistics · Immunization · Influenza vaccine · Reactogenicity · Vaccination · Drug-Induced Adverse Reactions · Influenza Virus Research Studies · Medicine · Pharmacovigilance and Adverse Drug Reactions · Emergency Medicine · Epidemiology · Immunology · Internal Medicine · Pediatrics
| Citations per year | 0.25 |
|---|---|
| Citation span | 2022 - 2022 (1) |
| Highly cited | No |